专题：Neuroendocrine Tumor Research Advances

This cluster of papers focuses on the epidemiology, classification, management, and treatment of neuroendocrine tumors, with a specific emphasis on pancreatic neuroendocrine tumors. It covers topics such as somatostatin receptor-based imaging and therapy, MEN1 syndrome, peptide receptor radionuclide therapy, genetic mutations associated with these tumors, and survival analysis.
最新文献
The Paradox of Grade 2 Pancreatic Neuroendocrine Tumors: G2a/G2b Subdivision in Patients With and Without Liver Metastases: A Retrospective Single-Center Analysis

article Full Text OpenAlex

Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

article Full Text OpenAlex

Advancing Therapeutic Strategies for Pancreatic Cancer: A Review of Surgical, Systemic and Diagnostic Innovations

article Full Text OpenAlex

New directions in MEN1 management: navigating the new clinical practice guidelines

review Full Text OpenAlex

Clinical Significance of an R1 Resection for Pancreatic Ductal Adenocarcinomas Treated by Intensive FOLFIRINOX Induction-Based Chemotherapy and Extended Pancreatectomies

article Full Text OpenAlex

The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials

article Full Text OpenAlex

A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias

article Full Text OpenAlex

Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis

article Full Text OpenAlex

Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma

article Full Text OpenAlex

Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)

article Full Text OpenAlex

近5年高被引文献
Overview of the 2022 WHO Classification of Thyroid Neoplasms

review Full Text OpenAlex 1019 FWCI135.1936

Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms

review Full Text OpenAlex 882 FWCI130.0556

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

article Full Text OpenAlex 830 FWCI108.9641

Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment

review Full Text OpenAlex 827 FWCI83.1884

European Journal of Endocrinology

paratext Full Text OpenAlex 587 FWCI0

Overview of the 2022 WHO Classification of Pituitary Tumors

review Full Text OpenAlex 558 FWCI72.8288

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends

review Full Text OpenAlex 490 FWCI116.6177

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

article Full Text OpenAlex 422 FWCI41.8558

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

article Full Text OpenAlex 410 FWCI95.6265

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

article Full Text OpenAlex 381 FWCI89.3292